Eli Lilly Full Year 2025 Financial ReportEli LillyEli Lilly's 2025 results show a 45% revenue increase to $65.2B, driven by Mounjaro and Zepbound sales. With strong growth in profits and an optimistic 2026 outlook, the company continues to lead in metabolic diseases and oncology treatments.
Eli Lilly 2025 H1 ReportFinancial statementsEli Lilly's 2025 H1 revenue surged 41% to $28.29B, driven by tirzepatide sales hitting $14.7B. Mounjaro and Zepbound shine as blockbuster drugs, boosting Lilly's global pharmaceutical ranking.
Eli Lilly Acquires SiteOne in $1B Pain Drug DealEli LillyEli Lilly has acquired SiteOne Therapeutics in a deal worth up to $1 billion to develop STC-004, a promising non-opioid NaV1.8 inhibitor for chronic pain, advancing next-gen, addiction-free pain therapies.
Lilly Challenges Medicare's Exclusion of Obesity DrugsEli LillyEli Lilly challenges CMS's 2026 Medicare Part D ruling that excludes coverage for obesity drugs like Zepbound and Wegovy, citing risks to patient care and provider autonomy amid rising concerns over healthcare access and costs.
Pharma's $158B U.S. Manufacturing SurgeMarket TrendMajor pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
Stylus Medicine Raises $85 Million!Eli LillyStylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
Semaglutide vs Tirzepatide in Weight LossSemaglutideA head-to-head clinical trial shows Tirzepatide significantly outperforms Semaglutide in weight loss and waist reduction among obese non-diabetic adults, with superior efficacy and comparable safety.
Eli Lilly's Q1 2025 Financial reportMarket TrendEli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
Nuclear Medicine Titans: The Battle in a $10 Billion MarketBayerExplore how pharma giants like Novartis, Bayer, AstraZeneca, BMS, and Eli Lilly are battling for dominance in the booming $10B radiopharmaceutical market with cutting-edge therapies and strategic acquisitions.
